Skip to main content
SpringerLink
Log in

Aspects of clinical pharmacology and bioavailability of azapropazone

  • Chapter
Azapropazone

  • 53 Accesses

Abstract

Clinical testing with azapropazone was begun in 1966 in Europe by Siegfried AG. Currently, azapropazone is available in numerous countries throughout the world for the treatment of arthritic conditions. Clinical development of azapropazone in the United States was initiated by AH Robins. Prior to their decision to terminate clinical development of azapropazone in USA, AH Robins accumulated experience in over 1600 patients on the effectiveness of the drug in rheumatoid arthritis and osteoarthritis. They also completed a preliminary study in patients with acute gout.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eberl, R and Fellman, N (eds) (1985). Standortbestimmung des Azapropazons. Rheuma Forum Sondernummer 2, 1–63

    Google Scholar 

  2. Templeton, JS (1983). Azapropazone. In: Huskisson, EC (ed), And-Rheumatic Drugs. (New York: Praeger Publishers), pp. 97–113

    Google Scholar 

  3. Jones, CJ (1976). The pharmacology and pharmacokinetics of azapropazone — a review. Curr Med Res Opin, 4, 3–16

    Article  PubMed  CAS  Google Scholar 

  4. Kline, BJ, Wood, JH and Beightol, LA (1983). The determination of azapropazone and its 6-hydroxy metabolite. Arzneim-Forsch (Drug Res), 33, 504–6

    CAS  Google Scholar 

  5. Greenblatt, DJ, Abernethy, DR, Morse, DS, Shader, RI and Harmhatz, JS (1984). Clinical importance of the interaction of diazepam and Cimetidine. N Engl J Med, 310, 1639–43

    Article  PubMed  CAS  Google Scholar 

  6. Frank, O (1977). The treatment of acute gouty arthritis. Adv Exp Med Biol, 76B, 288–90

    PubMed  CAS  Google Scholar 

  7. Dieppe, PA, Doherty, M, Whicher, JT and Walters, G (1981). The treatment of gout with azapropazone: clinical and experimental studies. Eur J Rheum Inflamm, 4, 392–400

    CAS  Google Scholar 

  8. Higgens, CS and Scott, JT (1984). The uricosuric action of azapropazone: dose-response and comparison with probenecid. Br J Clin Pharmacol, 18, 439–43

    PubMed  CAS  Google Scholar 

  9. Gibson, T, Simmonds, HA, Armstrong, RD, Fairbanks, LD and Rodgers, AV (1984). Azapropazone — a treatment for hyperuricaemia and gout? Br J Rheumatol, 23, 44–51

    Article  PubMed  CAS  Google Scholar 

  10. Ritch, AES, Perera, WNR and Jones, CJ (1982). Pharmacokinetics of azapropazone in the elderly. Br J Clin Pharmacol, 14, 116–9

    PubMed  CAS  Google Scholar 

  11. Breuing, KH, Gilfrich, H J, Meinertz, T and Jähnchen, E (1979). Pharmacokinetics of azapropazone following single oral and intravenous doses. Arzneimittel-Forschung/Drug Research, 29, 6, 971–2

    CAS  Google Scholar 

  12. Breuing, K-H, Gilfrich, H-J, Meinertz, T, Wiegand, U-W and Jähnchen, E (1981). Disposition of azapropazone in chronic renal and hepatic failure. Eur J Clin Pharmacol, 20, 147–55

    Article  PubMed  CAS  Google Scholar 

  13. Markus, FWHM (1980). Drugs to be taken with meals. Pharm-Int, ii, 1–8

    Google Scholar 

  14. Brown, CH and Pharm, MS (1988). Key pharmacokinetics of arthritis drugs. Effective counselling and clinical monitoring of patient response to these drugs will help avoid adverse reactions and ensure effective therapy. US Pharmacist, 13, 49–67

    Google Scholar 

  15. Leach, H (1976). The determination of azapropazone in blood plasma. Curr Med Res O pin, 4, 35–43

    Article  CAS  Google Scholar 

  16. Powell, RJ and Donn, KH (1984). Histamine H2-antagonist in perspective: mechanistic concepts and clinical implications. Am J Med, 77 (Suppl. 58), 57–84

    PubMed  CAS  Google Scholar 

  17. Greene, W (1984). Drug interactions involving Cimetidine — mechanisms, documentation, implications. Rev Drug Metab Drug Interact, 5, 25–51

    Article  CAS  Google Scholar 

  18. Geaney, DPI, Carver, JG, Davies, CL and Aronson, JK (1983). Pharmacokinetic investigation of the interaction of azapropazone with pnenytoin. Br J Clin Pharmacol, 15, 727–34

    PubMed  CAS  Google Scholar 

  19. Ochs, Hr, Greenblatt, DJ, Matlis, R and Weinbrenner, J (1985). Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and Cimetidine. Clin Pharmacol Ther, 38, 648–51

    Article  PubMed  CAS  Google Scholar 

  20. Delhotal-Landes, B, Flouvat, B, Liote, F et al. (1988). Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2 receptor antagonists (Cimetidine or ranitidine) in human volunteers. Clin Pharmacol Ther, 44, 442–52

    Article  PubMed  CAS  Google Scholar 

  21. Somogyi, A and Muirhead, M (1987). Pharmacokinetic interactions of Cimetidine 1987. Clin Pharmacok, 12, 321–66

    Article  CAS  Google Scholar 

Download references

Authors
  1. K. K. Maggon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. M. Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biomedical Sciences, McMaster University Faculty of Health Sciences, 1200 Main St W, Hamilton, Ontario, L8N 3Z5, Canada

    K. D. Rainsford

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Maggon, K.K., Lam, G.M. (1989). Aspects of clinical pharmacology and bioavailability of azapropazone. In: Rainsford, K.D. (eds) Azapropazone. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0713-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0713-3_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6806-2

  • Online ISBN: 978-94-009-0713-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation